Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post Marketing Trial (Phase IV) on the Safety, Tolerability And Efficacy of Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer

NCT03583944 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT03583944
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03583944 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post Marketing Trial (Phase IV) on the Safety, Tolerability And Efficacy of Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Breast Cancer
Lead sponsor
Eisai Inc.
Phase
Phase 4
Overall status
Completed
Start date
March 28, 2018
Completion date
June 28, 2019
Enrollment
200 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

breast neoplasms